HUNGARIAN EXPERIENCES WITH LEVODOPA/CARBIDOPA INTESTINAL GEL IN THE TREATMENT OF ADVANCED PARKINSON'S DISEASE

被引:0
|
作者
Nagy, Helga [1 ,2 ]
Takats, Annannaria [1 ]
Toth, Adrian [1 ]
Bereczki, Daniel [1 ]
Klivenyi, Peter [3 ]
Dezsi, Livia [3 ]
Dibo, Gyoergy [3 ]
Vecsei, Laszlo [3 ,4 ]
Kovacs, Norbert [5 ]
Aschermann, Zsuzsa [5 ]
Komoly, Samue, I [5 ]
Varannai, Lajos [6 ]
Zemlenyi, Gyoengyi [6 ]
Valikovics, Attila [6 ]
机构
[1] Semmelweis Egyet, Neurol Klin, H-1083 Budapest, Hungary
[2] Orszagos Orvosi Rehabil Int, Budapest, Hungary
[3] Szegedi Tudomonyegyetem, Neurol Klin, Szeged, Hungary
[4] MTA SZTE, Szeged, Hungary
[5] Pecsi Tudomanyegyetem, Neurol Klin, Pecs, Hungary
[6] Borsod Abauj Zemplen Megyei Korhoz, Neurol Osztoly, Miskolc, Hungary
来源
关键词
advanced Parkinson's disease; motor and non - motor fluctuations; disturbing dyskinesias; effectiveness of LCIG therapy; results in Hungary; DUODENAL LEVODOPA INFUSION; CONTINUOUS DOPAMINERGIC STIMULATION; CONTINUOUS DRUG-DELIVERY; INTRAJEJUNAL LEVODOPA; NONMOTOR SYMPTOMS; MOTOR; EFFICACY; MULTICENTER; SAFETY;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In the advanced Parkison's disease (PD) the late complications of levodopa therapy have to be considered: motor and/or non-motor fluctuations with or without disturbing dyskinesias. The non-motor fluctuations often influence the quality of life (QoL) in a much more negative way compared with the motor symptoms. In the treatment of advanced PD there are several device-aided methods - deep brain stimulation, apomorphine pump, levodopa/carbidopa intestinal gel (LCIG) - to improve the symptoms, the QoL, sometimes even in an individual, tailored custom form. The LCIG therapy was introduced in Hungary in 2011. Here we summarize the data of our patients: we have tested almost 60 patients and in 43 cases we have started this treatment. We analyze the duration of illness, levodopa therapy, motor and non-motor fluctuation of patients and present our experiences with the test phase and the chronic LCIG therapy via PEG/PEJ implantation. We paid attention to the surgery and device - depending side effects. Our experiences are similar to the international data. In patients selection "the right treatment, to the right patient, in the right time" is of importance.
引用
收藏
页码:385 / 389
页数:5
相关论文
共 50 条
  • [41] The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review
    Zhang, Xing-Ru
    Jiang, Zhi-Yu
    Zhang, Zeng-Rui
    Chen, Hui-Jun
    Wu, Ke
    He, Jin-Cai
    Xie, Cheng-Long
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 845 - 854
  • [42] Interim Results of Outpatient Levodopa-Carbidopa Intestinal Gel Titration in Advanced Parkinson's Disease
    Rodriguez, Ramon
    Lobatz, Michael
    Dubow, Jordan
    Eaton, Susan
    Hall, Coleen
    Chatamra, Krai
    Benesh, Janet A.
    ANNALS OF NEUROLOGY, 2015, 78 : S55 - S56
  • [43] Levodopa–Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review
    Karin Wirdefeldt
    Per Odin
    Dag Nyholm
    CNS Drugs, 2016, 30 : 381 - 404
  • [44] Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease
    Guthikonda, Lalitha N.
    Lyons, Kelly E.
    Pahwa, Rajesh
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2014, 3 (04) : 331 - 333
  • [45] Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease
    van Laar, T.
    Nyholm, D.
    Nyman, R.
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 133 (03): : 208 - 215
  • [46] Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease
    Fabbri, M.
    Zibetti, M.
    Beccaria, L.
    Merola, A.
    Romagnolo, A.
    Montanaro, E.
    Ferreira, J. J.
    Palermo, S.
    Lopiano, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (03) : 490 - 496
  • [47] Predictors of Retention for Carbidopa/Levodopa Intestinal Gel in Parkinson Disease
    Nagy, A.
    Davis, T.
    Hassell, T.
    Hedera, P.
    Isaacs, D.
    Koons, H.
    Phibbs, F.
    Afrow, S.
    Fang, J.
    MOVEMENT DISORDERS, 2019, 34
  • [48] Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease Patients Receiving ≥ 2000 mg Daily Dose of Levodopa
    Zadikoff, Cindy
    Boyd, James
    Dubow, Stephanie
    Bergmann, Lars
    Robieson, Weining
    Ijacu, Horia
    Benesh, Janet
    NEUROLOGY, 2018, 90
  • [49] Safety of Levodopa-carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease Patients Receiving=2000 mg Daily Dose of Levodopa
    Zadikoff, Cindy
    Boyd, James T.
    Dubow, Stephanie
    Bergmann, Lars
    Robieson, Weining Z.
    Ijacu, Horia
    Benesh, Janet
    MOVEMENT DISORDERS, 2018, 33 : S90 - S91
  • [50] Safety of levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease patients receiving=2000 mg daily dose of levodopa
    Zadikoff, C.
    Boyd, J.
    Dubow, S.
    Bergmann, L.
    Robieson, W.
    Ijacu, H.
    Benesh, J.
    MOVEMENT DISORDERS, 2017, 32